HOME >> MEDICINE >> NEWS
New centers boost muscular dystrophy research

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD), parts of the National Institutes of Health (NIH), have funded three new cooperative research centers for the muscular dystrophies (MD), a group of genetic diseases that result in muscle weakness and wasting. The three institutes will fund the centers at up to $1 million in direct costs per center per year for 5 years. The NIH expects to fund up to two additional centers in future years.

The centers, principal investigators, funding agencies and planned research include:

  • The University of Pittsburgh, Joseph C. Glorioso, Ph.D. (NIAMS). Scientists here will study gene and stem cell therapies to treat muscle disease, in particular Duchenne muscular dystrophy. One project will attempt to deliver and engraft muscle stem cells into diseased heart tissue without causing an immune response. Researchers will also use herpesvirus vectors in functional genomics studies to discover and characterize factors that guide stem cell maturation into muscle. In collaboration with scientists at the University of Missouri and Ohio State University, adeno-associated viral vectors will be exploited in preclinical studies in a dog MD model seeking the most effective ways to deliver gene therapy. Clinical disease outcomes will be carefully defined in patients with Duchenne and limb-girdle muscular dystrophies for the preparation of phase I gene therapy safety trials.
  • The University of Washington, Seattle, Jeffrey S. Chamberlain, Ph.D. (NICHD). This center will conduct studies to develop new gene therapies for Duchenne muscular dystrophy. Researchers have already achieved some success with viral vectors in delivering genes to mouse muscle. Investigators will use animal models to study several aspects of gene therapy to guid
    '"/>


Contact: Ray Fleming
flemingr@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
14-Oct-2003


Page: 1 2 3

Related medicine news :

1. Advertising by academic medical centers may risk eroding public trust, says study
2. Dedicated hospital stroke centers improve quality of acute care
3. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
4. NIA establishes new demography centers to enhance knowledge about older americans
5. Study compares overnight dialysis to treatment in centers
6. Florida study shows surgical mishaps more likely in physician offices than surgery centers
7. HHS announces new regional centers for biodefense research
8. Assessment finds gaps in access to nations trauma centers
9. National Census finds most US counties dont have enough adult day centers
10. New centers to research, reduce asthma disparities
11. UNC among 10 U.S. medical centers tapped to study living donor liver transplants

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New centers boost muscular dystrophy research

(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: